MicroLactin® and Equine
in EquineVeterinary Practice. Journal of Equine Veterinary Science. 2005;
A clinical survey was performed of 58 horses that were treated with Duralactin® Equine for a variety of inflammatory conditions. Additional therapies were included as necessary. Improvement was seen in 86% of the cases.
Materials & Methods
Each horse received 1 scoop of Duralactin Equine (7,000 mg MicroLactin) twice daily with food. Additional therapies were prescribed as necessary. The survey includes a large range of breeds and ages (0.75-36 years). There were 20 mares, 36 geldings, and 2 stallions.
This study did not have a control or placebo consort. Additionally, it is understood that some of the horses conditions were acute and some may have resolved without intervention.
Results & Discussion
Inflammation was reduced in 86% of the cases (44/51). Seven horses were lost to follow-up. The inflammatory conditions included in the survey are listed in Table.1
This clinical survey shows clinical improvement after the supplementation of MicroLactin® in a variety of equine inflammatory conditions. The results can direct future placebo-controlled trials in these and other inflammatory conditions. MicroLactin can affect inflammation throughout the body.